This inventor holds 1 USPTO granted patent. Top assignee: Boehringer Ingelheim International Gmbh. Active years: 2009.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2009
Title: The Innovative Contributions of Rene' Marc Lemieux in the Treatment of Inflammatory Diseases
Introduction: Rene' Marc Lemieux, an accomplished inventor based in Plantsville, CT, has made significant strides in the field of medicinal chemistry. His notable invention focuses on a class of compounds that offer promising treatments for inflammatory diseases. With one patent to his name, Lemieux continues to contribute to advancements in healthcare and pharmacology.
Latest Patents: Rene' Marc Lemieux is credited with a patent titled "Substituted benzylimidazoles useful for the treatment of inflammatory diseases." This patent outlines a series of derivatives of substituted benzylimidazoles, providing methods for their synthesis. These compounds play a vital role in addressing various inflammatory conditions, showcasing Lemieux's dedication to improving therapeutic options.
Career Highlights: Rene' Marc Lemieux is currently associated with Boehringer Ingelheim International GmbH, where he engages in pioneering research and development. His work reflects the company's commitment to bringing innovative solutions to the pharmaceutical market. Through dedicated research efforts, Lemieux has advanced the field of medicinal chemistry, moving closer to effective treatments for patients suffering from inflammatory diseases.
Collaborations: Throughout his career, Lemieux has collaborated with talented individuals such as Jin Mi Kim and Bryan Patrick McKibben. These partnerships have fostered an environment of innovation, allowing them to share knowledge and expertise that drives research and product development within the realm of pharmaceuticals.
Conclusion: Rene' Marc Lemieux stands out as an inventive force in the pharmaceutical industry. His patent on substituted benzylimidazoles illustrates his commitment to developing effective treatments for inflammatory diseases. As he continues his work at Boehringer Ingelheim International GmbH, his contributions pave the way for future advancements in medicine, benefitting patients and the healthcare field alike.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile